Dec 12, 2012 · Among the companies whose shares are making notable moves in Wednesday's session are YM BioSciences Inc. YMI, Centerra Gold Inc. CG.T and Just Energy Group YM BIOSCIENCES INC - YM - Stock Price & News | The Motley Fool Real time YM BIOSCIENCES INC (YM) stock price quote, stock graph, news & analysis. YM BioSciences's Strange Journey Comes To A Strange ...
Gilead Sciences to Acquire YM Biosciences News provided by. YM BioSciences Inc. and holders of warrants and stock options will receive a cash payment equal to the difference between U.S. $2.95
YM BioSciences Inc. Plan of Arrangement with Gilead Sciences, Inc. Endorsed by Leading Independent Proxy Advisors ISS and Glass Lewis - Canada Newswire Fri, Dec 21, 2012 12:19 PM Gilead to Buy YM BioSciences - Analyst Blog | Nasdaq Dec 13, 2012 · We have a Neutral stance on YM BioSciences. The stock carries a Zacks #2 Rank (Buy) in the short run. GILEAD SCIENCES (GILD): Free Stock Analysis Report. YM Biosciences Stock Chart - YMI - Investors Hub
YM BioSciences Inc. was a Canadian drug development company primarily focused on The company was listed on the Toronto Stock Exchange and the New York Stock Exchange. YM BioSciences was the first company from any
YM BioSciences Inc. is a drug development company primarily focused on advancing CYT387, an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number YM BIOSCIENCES, INC. & TERABEAM, INC. – Pennystock picks ... YM BIOSCIENCES, INC. & TERABEAM, INC. November 5, 2006 July 25, 2017 PennyStock Wizard Stock probably slumped on news about ethanol and corrosive tanks, but this may not be a long-standing problem. Selects exclusive distributor for Asia Pacific and South Africa. To begin testing new ethanol-biodiesel blend with a Washington state transit YM Biosciences’ Fiscal 2006 Financial Results | GEN ... Sep 22, 2006 · YM BioSciences reported operational and financial results for the fourth quarter and the 2006 fiscal year, ended June 30, 2006. “In fiscal 2006, we made exceptional progress in …
2 Nov 2018 Immunovaccine Inc. BOUGHT DEAL, FEBRUARY 2018. Satellos Bioscience YM BioSciences Inc. MERGER & ACQUISITION ADVISORY
David Allan Finance and Life Sciences Consultant YM BioSciences was itself acquired by Gilead Sciences in 2013 for US$510 million. The principals of the investment banking firm Bloom Burton featured centrally in many of the public financings concluded by YM, were invaluable in the M&A projects and provided the definitive fairness opinion to the YM Board on the Gilead acquisition.
Formerly a Governor of the Toronto Stock Exchange, the Principal has been a member He was the Founding Chairman of YM BioSciences Inc and CEO from
Glassdoor gives you an inside look at what it's like to work at YM BioSciences, including salaries, reviews, office photos, and more. This is the YM BioSciences company profile. All content is posted anonymously by employees working at YM BioSciences. YM BioSciences Inc., Mississauga, Ontario YM BioSciences Inc. is a cancer drug development company. It licenses research products from academic institutions and other biotechnology companies which it then develops. Its clinical development portfolio includes four different anti-cancer compounds in a number of formulations targeting seven different tumours or stages of cancer. Ym Biosciences Inc - lawinsider.com ym biosciences inc – agreement and plan of merger by and among ym biosciences inc., ym biosciences usa inc., ym biosciences u.s. operations inc., eximias pharmaceutical corporation and orbimed advisors, llc, as stockholder representative april 13, 2006 (september 22nd, 2008) Gilead Sciences to buy YM Biosciences for $510M Dec 12, 2012 · Shares of YM BioSciences rose $1.25, or 77 percent, to $2.88 in afternoon trading. Earlier the stock traded at a 52-week high of $2.92. Gilead said YM BioScience's most advanced drug is a possible treatment for blood diseases, inflammatory disorders, and certain cancers.
Buy, Sell or Hold: YM BioSciences (YM-T) — Stock ... YM BioSciences (YM-T) January 24, 2007 Tesmilifene is the 1st compound they’ll have pivotal phase 3 results on and the stock should move up strongly. Gilead Sciences Completes Acquisition of YM BioSciences Shareholders of YM on this date will be entitled to receive U.S. $2.95 per common share in cash, and holders of warrants and stock options will be entitled to receive a cash payment equal to the difference between U.S. $2.95 and the exercise price of such warrant or stock option. About Gilead Sciences ASCO '11: YM BioSciences Attracts Wall Street - TheStreet Jun 04, 2011 · CHICAGO ( TheStreet) -- YM BioSciences ()was the beneficiary of the first Wall Street scrum of ASCO 2011 Friday afternoon. Dozens of investors and analysts jockeyed for position around a Gilead to Buy YM BioSciences - Business Finance, Stock ...